Translation, cultural adaptation and validation of the Danish version of the haematological malignancy patient-reported outcome measure (HM-PRO).

IF 2.9 Q2 HEALTH CARE SCIENCES & SERVICES
Sam Salek, Sören Möller, Niels Abildgaard, Tine Rosenberg, Maria Torp Larsen, Peter Asdahl, Kasper Kofod Pedersen, Marie Therese Lassen, Christen Lykkegaard Andersen, Lene Kongsgaard Nielsen
{"title":"Translation, cultural adaptation and validation of the Danish version of the haematological malignancy patient-reported outcome measure (HM-PRO).","authors":"Sam Salek, Sören Möller, Niels Abildgaard, Tine Rosenberg, Maria Torp Larsen, Peter Asdahl, Kasper Kofod Pedersen, Marie Therese Lassen, Christen Lykkegaard Andersen, Lene Kongsgaard Nielsen","doi":"10.1186/s41687-025-00869-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Assessment of cancer patients´ quality of life (QoL) through patient-reported outcomes (PRO) during and after treatment is gaining ground. The HM-PRO is the first generic Haematological Malignancy specific PRO measure for use in clinical practice and clinical trials. Such generic tools are needed in Denmark. The study aim was to translate and cross-culturally adapt the HM-PRO into Danish and evaluate the psychometric properties.</p><p><strong>Methods: </strong>Translation and cross-cultural adaptation of the original English HM-PRO into Danish followed established guidelines. After cognitive debriefing interviews, it underwent psychometric testing with a variety of hematologic malignancies. Construct validity, internal consistency, dimensionality, item response theory (IRT) and differential item functioning were investigated.</p><p><strong>Results: </strong>295 patients were included for psychometric evaluation; confirmatory factor and bifactor analyses for both HM-PRO parts provided good evidence to support the suggested factor structure (Cronbach's-α Part-A = 0.81, Part-B = 0.84; Part-A CFA CFI = 0.922, TLI = 0.912; bi-factor CFI = 0.989, TLI = 0.978). IRT showed good item-fit and factor loadings and absence of local dependency.</p><p><strong>Conclusion: </strong>The HM-PRO has demonstrated favourable psychometric properties and can be used broadly within the Danish Healthcare system to monitor symptoms as well as QoL impact of patients with haematological cancer and optimize patient engagement during routine cancer care. WHAT IS THE NEW ASPECT OF YOUR WORK?: In response to the intention of the Danish Health Authority to systematically collect PRO data on health-related QoL in Danish cancer patients, this study investigates the translation and cross-cultural adaptation of the original English HM-PRO into Danish. WHAT IS THE CENTRAL FINDING OF YOUR WORK?: Few issues were met with the translation and adaptation of HM-PRO into Danish. WHAT IS (OR COULD BE) THE SPECIFIC CLINICAL RELEVANCE OF YOUR WORK?: The HM-PRO has demonstrated favourable psychometric properties and can be used broadly within the Danish Healthcare system to monitor symptoms as well as QoL impact of patients with haematological cancer and optimize patient engagement during routine cancer care.</p>","PeriodicalId":36660,"journal":{"name":"Journal of Patient-Reported Outcomes","volume":"9 1","pages":"43"},"PeriodicalIF":2.9000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12040771/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Patient-Reported Outcomes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41687-025-00869-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Assessment of cancer patients´ quality of life (QoL) through patient-reported outcomes (PRO) during and after treatment is gaining ground. The HM-PRO is the first generic Haematological Malignancy specific PRO measure for use in clinical practice and clinical trials. Such generic tools are needed in Denmark. The study aim was to translate and cross-culturally adapt the HM-PRO into Danish and evaluate the psychometric properties.

Methods: Translation and cross-cultural adaptation of the original English HM-PRO into Danish followed established guidelines. After cognitive debriefing interviews, it underwent psychometric testing with a variety of hematologic malignancies. Construct validity, internal consistency, dimensionality, item response theory (IRT) and differential item functioning were investigated.

Results: 295 patients were included for psychometric evaluation; confirmatory factor and bifactor analyses for both HM-PRO parts provided good evidence to support the suggested factor structure (Cronbach's-α Part-A = 0.81, Part-B = 0.84; Part-A CFA CFI = 0.922, TLI = 0.912; bi-factor CFI = 0.989, TLI = 0.978). IRT showed good item-fit and factor loadings and absence of local dependency.

Conclusion: The HM-PRO has demonstrated favourable psychometric properties and can be used broadly within the Danish Healthcare system to monitor symptoms as well as QoL impact of patients with haematological cancer and optimize patient engagement during routine cancer care. WHAT IS THE NEW ASPECT OF YOUR WORK?: In response to the intention of the Danish Health Authority to systematically collect PRO data on health-related QoL in Danish cancer patients, this study investigates the translation and cross-cultural adaptation of the original English HM-PRO into Danish. WHAT IS THE CENTRAL FINDING OF YOUR WORK?: Few issues were met with the translation and adaptation of HM-PRO into Danish. WHAT IS (OR COULD BE) THE SPECIFIC CLINICAL RELEVANCE OF YOUR WORK?: The HM-PRO has demonstrated favourable psychometric properties and can be used broadly within the Danish Healthcare system to monitor symptoms as well as QoL impact of patients with haematological cancer and optimize patient engagement during routine cancer care.

丹麦版血液学恶性肿瘤患者报告结果测量(HM-PRO)的翻译、文化适应和验证
背景:通过患者报告预后(PRO)评估癌症患者在治疗期间和治疗后的生活质量(QoL)正在取得进展。HM-PRO是第一个用于临床实践和临床试验的血液学恶性肿瘤特异性PRO测量方法。丹麦需要这样的通用工具。本研究的目的是翻译和跨文化适应HM-PRO到丹麦,并评估心理测量的性质。方法:将原英语《HM-PRO》翻译成丹麦语并进行跨文化改编。在接受认知汇报访谈后,患者接受了多种血液恶性肿瘤的心理测量测试。构效度、内部一致性、维度、项目反应理论和差异项目功能进行了研究。结果:纳入295例患者进行心理测量评估;验证性因子分析和双因子分析均为提出的因子结构提供了良好的证据支持(Cronbach’s-α a部分= 0.81,b部分= 0.84;Part-A CFA CFI = 0.922, TLI = 0.912;双因子CFI = 0.989, TLI = 0.978)。IRT显示出良好的项目拟合和因子负载,并且没有局部依赖性。结论:HM-PRO具有良好的心理测量特性,可以在丹麦医疗保健系统中广泛使用,以监测血液学癌症患者的症状和生活质量影响,并优化患者在常规癌症护理中的参与度。你工作的新方面是什么?为了响应丹麦卫生当局系统收集丹麦癌症患者健康相关生活质量的PRO数据的意图,本研究调查了原英文HM-PRO翻译成丹麦语的翻译和跨文化改编。你工作的中心发现是什么?HM-PRO翻译和改编成丹麦语时遇到的问题很少。什么是(或可能是)你的工作的具体临床相关性?HM-PRO已经证明了良好的心理测量特性,可以在丹麦医疗保健系统中广泛使用,以监测血液学癌症患者的症状和生活质量影响,并优化患者在常规癌症护理期间的参与度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Patient-Reported Outcomes
Journal of Patient-Reported Outcomes Health Professions-Health Information Management
CiteScore
3.80
自引率
7.40%
发文量
120
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信